ZIAGEN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
ZIAGEN by GSK is [see microbiology ()] . Approved for human immunodeficiency virus (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 1998.
Drug data last refreshed 16h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIAGEN is an oral small-molecule antiretroviral approved in 1998 by GSK. The drug's specific mechanism of action and indications are not detailed in available data, but its 25-year market presence suggests established use in a chronic disease state. It is formulated as a tablet for convenient oral administration.
$0.112MPart D
LOE ApproachingDeclining
Low commercial intensity with approaching loss of exclusivity suggests a mature brand with minimal ongoing team expansion or hiring.
Mechanism of Action
[see Microbiology ()] .
Clinical Trials (1)
ZIAGEN® Post-marketing Surveillance
Started Nov 2010
671 enrolled
Infection, Human Immunodeficiency Virus I
Worked on ZIAGEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.